Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2016-11-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于对暂时闲置自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the implementation of cash management of temporarily idle own funds. It details the purchase of bank wealth management products, including amounts, expected returns, risk ratings, and risk control measures. The document references a prior shareholder meeting resolution and provides specifics on financial products purchased and their status. It does not contain comprehensive financial statements or detailed financial performance data. The document length is 3432 characters, which is relatively short and focused on a specific financing activity. This fits the category of Capital/Financing Update (CAP), as it updates on the company's use of idle funds for cash management and investment products. It is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the best classification is CAP with high confidence.
2016-11-25 Chinese
2016年限制性股票激励计划首次授予的激励对象名单
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement listing the recipients of a restricted stock incentive plan granted by the company in 2016. It includes names, positions, and stock allocation details. This type of document relates to share-based compensation and changes in share ownership among management and employees. It is not a financial report, earnings release, or management discussion. It is also not a proxy statement or voting result announcement. The document is an announcement about the allocation of restricted stock incentives, which falls under the category of Capital/Financing Update (CAP) because it concerns equity incentives and capital structure changes related to stock grants.
2016-11-07 Chinese
第二届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by 普莱柯生物工程股份有限公司. It details the convening of the board meeting, attendance, and the approval of a restricted stock grant to incentive recipients. There is no financial data or comprehensive report content, but rather a formal announcement of a board decision. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short and focused on a specific board resolution, not a full report or financial statement.
2016-11-07 Chinese
独立董事关于首次向激励对象授予限制性股票的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the initial grant of restricted shares to incentive recipients, referencing relevant laws and company regulations. It discusses the grant date, compliance with incentive plan conditions, and approval of the stock grant. The document is short (534 characters) and is a formal opinion or certification related to a share incentive plan, not a full report or announcement of a financing event. It does not contain financial statements or detailed financial data. This fits best under Regulatory Filings (RNS) as it is a compliance-related statement and independent opinion rather than a full report or capital change announcement.
2016-11-07 Chinese
关于首次向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the initial grant of restricted shares to incentive recipients. It details the stock incentive plan, including the number of shares granted, the grant date, the recipients, and the terms of the stock restrictions. It also includes legal opinions and compliance with relevant laws and regulations. There are no financial statements or comprehensive financial performance data presented, nor is this a report or presentation. The document is a formal announcement about a share-based incentive plan, which fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through issuance of shares to employees as incentives.
2016-11-07 Chinese
第二届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by 普莱柯生物工程股份有限公司. It details the approval of a restricted stock grant to incentive recipients, including the meeting date, attendance, and voting results. There is no financial report, earnings data, or detailed analysis present. The document is a corporate governance announcement related to board/supervisory decisions rather than a full management report or financial filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified under Board/Management Information (MANG) as it concerns a board resolution and management decision on stock incentives.
2016-11-07 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.